These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16752880)

  • 1. Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor.
    Gacci M; Serni S; Lapini A; Giubilei G; Dal Canto M; Paladini S; Curotto A; Gallo F; Carmignani G; Carini M
    Arch Ital Urol Androl; 2006 Mar; 78(1):5-10. PubMed ID: 16752880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder.
    Babjuk M; Kostírová M; Mudra K; Pecher S; Smolová H; Pecen L; Ibrahim Z; Dvorácek J; Jarolím L; Novák J; Zima T
    Eur Urol; 2002 Jan; 41(1):34-9. PubMed ID: 11999463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer.
    Mungan NA; Vriesema JL; Thomas CM; Kiemeney LA; Witjes JA
    Urology; 2000 Nov; 56(5):787-92. PubMed ID: 11068302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
    Mian C; Lodde M; Haitel A; Vigl EE; Marberger M; Pycha A
    Urology; 2000 Feb; 55(2):223-6. PubMed ID: 10688083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
    Serretta V; Lo Presti D; Vasile P; Gange E; Esposito E; Menozzi I
    Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder.
    Mian C; Lodde M; Haitel A; Egarter Vigl E; Marberger M; Pycha A
    Urology; 2000 Aug; 56(2):228-31. PubMed ID: 10925083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
    Couffignal C; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Mentre F; Cussenot O; Grandchamp B
    Urology; 2015 Dec; 86(6):1185-90. PubMed ID: 26364695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
    Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
    Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
    Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
    Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience.
    El-Assmy A; Abou-El-Ghar ME; Refaie HF; Mosbah A; El-Diasty T
    BJU Int; 2012 Dec; 110(11 Pt B):E622-7. PubMed ID: 22757606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
    Schulze M; Stotz N; Rassweiler J
    J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer.
    Zhang YR; Shi L; Wu H; Tang DD; Wang SM; Liu HM; Zhang LR; Song DK
    Tumori; 2014; 100(6):660-6. PubMed ID: 25688500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [One-stage transurethral resection of the urinary bladder and the prostate in patients with superficial cancer of the urinary bladder combined with benign prostatic hyperplasia].
    Karaguzhin SG; Merinov DS; Martov AG
    Urologiia; 2005; (5):17-21. PubMed ID: 16281833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].
    Sánchez-Carbayo M; Urrutia M; Hernández-Cerceño ML; González de Buitrago JM; Navajo JA
    Med Clin (Barc); 2000 Mar; 114(10):361-6. PubMed ID: 10786344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas.
    Pina-Cabral L; Santos L; Mesquita B; Amaro T; Magalhães S; Criado B
    Clin Transl Oncol; 2007 Nov; 9(11):731-6. PubMed ID: 18055328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the diagnostic accuracy of UBC
    Styrke J; Henriksson H; Ljungberg B; Hasan M; Silfverberg I; Einarsson R; Malmström PU; Sherif A
    Scand J Urol; 2017 Aug; 51(4):293-300. PubMed ID: 28422550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.